Cephalosporins Should Be the Preferred Oral Antibiotics for Empiric Treatment of Outpatient Acute Pyelonephritis
When treating an outpatient suspected pyelonephritis, consider using a cephalosporin orally as your initial empiric choice unless local resistance patterns strongly dictate otherwise. While fluoroquinolones and TMP-SMX remain options, favoring a cephalosporin may improve stewardship outcomes without compromising coverage for this common condition.
This article provides a clear recommendation regarding the optimal choice of oral antibiotics for empiric management of acute pyelonephritis in the outpatient setting, which is a common and potentially serious ED presentation. While fluoroquinolones and TMP-SMX have historically been the go-to agents according to consensus guidelines, this review argues for a shift toward cephalosporins as the preferred first-line oral therapy. The rationale centers on balancing effective coverage against concerns surrounding antimicrobial stewardship and potential adverse effects associated with older regimens. Choosing the right agent is critical not only for achieving clinical cure but also for mitigating risks of complications like sepsis or acute kidney injury.